HF
PTGX icon

HRT Financial’s Protagonist Therapeutics PTGX Stock Holding History

HRT Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,470
Closed -$629K – 3859
2025
Q3 		$629K Buy
+9,470
New +$538K ﹤0.01% 1756
2025
Q2 		– Sell
-69,242
Closed -$3.35M – 3364
2025
Q1 		$3.35M Buy
69,242
+61,217
+763% +$2.57M 0.02% 593
2024
Q4 		$309K Buy
+8,025
New +$350K ﹤0.01% 1697
2024
Q1 		– Sell
-73,126
Closed -$1.68M – 2933
2023
Q4 		$1.68M Buy
+73,126
New +$1.28M 0.01% 735
2023
Q1 		– Sell
-125,119
Closed -$1.36M – 3052
2022
Q4 		$1.36M Sell
125,119
-88,978
-42% -$751K 0.02% 761
2022
Q3 		$1.8M Buy
+214,097
New +$2.03M 0.02% 643
2021
Q1 		– Sell
-18,061
Closed -$364K – 3063
2020
Q4 		$364K Buy
+18,061
New +$389K 0.01% 1188

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

HRT Financial's PTGX Position: Q4 2025 in Review

HRT Financial sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 9,470 shares — an estimated $629K sold.

HRT Financial first reported a position in PTGX in Q4 2020 and held it in 7 quarters. The position peaked at $3.35M in Q1 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • HRT Financial reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 9,470 Protagonist Therapeutics shares in Q4 2025, an estimated $629K.
  • HRT Financial first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 7 quarters.
  • HRT Financial's Protagonist Therapeutics position peaked at $3.35M in Q1 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.